Загрузка...
Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
Anti-EGFR mAb (cetuximab or panitumumab) and anti-VEGF mAb (bevacizumab) are the two main targeted agents available for RAS wild-type (WT) metastatic colorectal cancer (mCRC) treatment. Nonetheless, three head-to-head clinical trials evaluating anti-EGFR mAb vs -VEGF mAb in first-line treatment fail...
Сохранить в:
| Опубликовано в: : | Cancer Manag Res |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6388996/ https://ncbi.nlm.nih.gov/pubmed/30863179 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S196170 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|